The Li-Fraumeni syndrome (LFS): A model for the initiation of p53 signatures in the distal fallopian tube

Journal of Pathology

Volumn 220, Issue 1, 2010, Pages 17-23

  Xian, Wa ^a   Miron, Alexander ^b   Roh, Michael ^a   Semmel, Dana R ^a   Yassin, Yosuf ^a,b   Garber, Judy ^b   Oliva, Esther ^c   Goodman, Annekathryn ^c   Mehra, Karishma ^a   Berkowitz, Ross S ^a   Crum, Christopher P ^a   Quade, Bradley J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRCA; Fallopian tube; Li Fraumeni syndrome; Ovarian cancer; p53; p53 signature; Serous cancer

Indexed keywords

HISTONE H2AX; KI 67 ANTIGEN; PROTEIN P53;

ADVANCED CANCER; ARTICLE; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; EXON; FAMILIAL CANCER; FEMALE; GENE DELETION; GENE INACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LOSS OF FUNCTION MUTATION; MUTATION; NUCLEOTIDE REPEAT; OVARY CANCER; PELVIC SEROUS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE REPEAT; TUMOR LOCALIZATION; UTERINE TUBE; UTERINE TUBE CARCINOMA; UTERINE TUBE MUCOSA;

CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, P53; GERM-LINE MUTATION; HUMANS; IMMUNOPHENOTYPING; LI-FRAUMENI SYNDROME; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73649131656     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2624     Document Type: Article

References (30)

1. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle 2009;8:731-735.
2. Brewer MA, Mitchell MF, Bast RC. Prevention of ovarian cancer. In Vivo 1999;13:99-106.
3. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994;73:1859-1864.
4. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-1197.
5. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004;191:718-732.
6. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingooophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:58-64.
7. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, et al. Risk-reducing salpingooophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005;23:127-132.
8. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005;106(6): 1327-1334.
9. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002;87(1):52-56.
10. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCApositive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25(25):3985-3990.
11. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31(2): 161-169.
12. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26(25):4160-4165.
13. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008;27(1): 1-9.
14. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211(1): 26-35.
15. Saleemuddin A, Folkins AK, Garrett L, Garber J, Muto MG, Crum CP, et al. Risk factors for a serous cancer precursor ('p53 signature') in women with inherited BRCA mutations. Gynecol Oncol 2009;115:108- 111.
16. Thiriet C, Hayes JJ. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 2005;18:617-622.
17. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-456.
18. Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol 2009;39(suppl 1):S27-31; Epub 16 December 2008 [review].
19. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997;3(9):390-395.
20. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008;109:168-173.
21. Piek JM, van Diest PJ, Verheijen RH, Kenemans P. Cell cycle-related proteins p21 and bcl-2: markers of differentiation in the human fallopian tube. Histopathology 2001;38:481-482.
22. Köbel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 2008;10:e22.
23. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-1344.
24. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE. Methylation not a frequent 'second hit' in tumors with germline BRCA mutations. Fam Cancer 2009;[Epub ahead of print].
25. Gras E, Cortes J, Diez O, Alonso C, Matias-Guiu X, Baiget M, et al. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 2001;92:787-795.
26. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009;69(8): 3625-3633.
27. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
28. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-162.
29. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-603. Erratum in: N Engl J Med 2003; 348: 674.
30. Senoo M, Pinto F, Crum CP, McKeon F. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007;129:523-536.